Frans Van de Werf
About
In The Last Decade
Frans Van de Werf
748 papers receiving 36.8k citations
Hit Papers
Peers
Comparison fields: 5 of 194
- Cardiology and Cardiovascular Medicine 29.8k
- Surgery 11.9k
- Radiology, Nuclear Medicine and Imaging 9.8k
- Internal Medicine 4.1k
- Pulmonary and Respiratory Medicine 2.9k
Countries citing papers authored by Frans Van de Werf
This map shows the geographic impact of Frans Van de Werf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frans Van de Werf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frans Van de Werf more than expected).
Fields of papers citing papers by Frans Van de Werf
This network shows the impact of papers produced by Frans Van de Werf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frans Van de Werf. The network helps show where Frans Van de Werf may publish in the future.
Co-authorship network of co-authors of Frans Van de Werf
This figure shows the co-authorship network connecting the top 25 collaborators of Frans Van de Werf. A scholar is included among the top collaborators of Frans Van de Werf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frans Van de Werf. Frans Van de Werf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 6 | |
| 2 | 19 | |
| 3 | 10 | |
| 4 | 82 | |
| 5 | 53 | |
| 6 | 60 | |
| 7 | Placental growth factor increases regional myocardial blood flow and function in a new porcine model of chronic myocardial ischemia | 1 |
| 8 | 166 | |
| 9 | Predictors of sudden cardiac death change with time after myocardial infarction: Results from the VALIANT Trial | 4 |
| 10 | 102 | |
| 11 | Understanding time to treatment in acute myocardial infarction: insights from ASSENT 3 plus | 1 |
| 12 | Higher Aspirin Dose is Associated with Reduced Mortality and More Serious Bleeding in Patients with Recent Cerebrovascular or Coronary Ischemic Events: Insights from the BRAVO Trial | 1 |
| 13 | QRS duration at rest predicts maximal exercise performance in adult patients with repaired tetralogy of Fallot | 1 |
| 14 | Optimal dosing of a glycoprotein IIb/IIIa antagonist with simplified renal-based algorithm: pharmacodynamic and clinical findings from PARAGON B | 0 |
| 15 | Therapeutic margin of safety with weight-optimized dosing of tenecteplase | 1 |
| 16 | Higher aPTTs associated with worse outcomes after thrombolytic therapy with reduced-dose heparin: results from Assent-2 | 2 |
| 17 | A Comparison of intracranial hemorrhage rates in patients treated with rtPA and tPA-TNK: impact of gender, age and low body weight | 4 |
| 18 | Comparison of fundamental and second harmonic integrated backscatter measurements in normal myocardial tissue | 6 |
| 19 | 92 | |
| 20 | 297 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.